Hear ye! Hear ye! I have an announcement to make. About 3 months ago, a committee formed to explore the possibility of creating a new conference series for adults with type 1 diabetes. Most conferences are currently geared towards all types of diabetes, but a group of us felt there should be more for the unique challenges that are posed to adults living with type 1.

With that in mind, we are conducting an interest study for the conference. Who would you like to see at the conference? Tell us what is missing from Type 1 diabetes (besides the obvious **cure**). This will help us with programming, as well as securing sponsorships for the event. Besides giving you all you want from the latest and greatest in type 1 diabetes - you have a chance to leave your mark on this revolutionary event. At the end of the survey, there is a question about creating a name for the conference. The committee will choose the winning name. The winner will receive an autographed copy of Know Your Numbers, by Amy Tenderich and Dr. Richard Jackson. The second and third places prizes are a Six Until Me mug and a Diabetes Mine mug, donated by Kerri Morrone and Amy Tenderich.

The survey closes on Friday, September 7, 2007 so don't miss your opportunity to voice your opinion. Take the survey today!!

Remember the A-Game suggestions I dangled for Eli Lilly to tap for performance enhancement? Well here it comes. I called Eli Lilly headquarters to speak with the Chairman and CEO, Mr. Sidney Taurel but I was directed to their idea submission form (which consequently didn't work). Oh boy, Sid. I'm a little disappointed. So here goes - my idea is going free for all when you could've had it, first. Let's call this new and improved product Beta Juice. It delivers the essential functions of a fully operational beta cell. It produces: insulin, amylin and c-peptide. Here's why insulin should always come equipped with the other two...

Insulin brings sugar to the cells to keep our energy levels sufficient for life, homeostasis and (if we're lucky) some energy for the gym. Amylin is a controlling agent for appetite, gastric emptying and tells the liver to dispatch glucose. It is also shown to have an impact on lipolysis --- the metabolism of stored fat. Until recently C-peptide was nothing more than a number used to decipher if you were a type 1 or a type 2 diabetic. However, recent scientific studies have shown C-peptide protects small vessels from the complications associated with diabetes. The Reuters Health article is titled C-Peptide Replacement Improves Early Diabetic Neuropathy.

The American Diabetes Association promotes the ABC's of Diabetes Care in an effort to educate diabetics on controlling their disease. The ABC's of diabetes care refer to a patient's Hemoglobin A1c, blood pressure, and cholesterol. A diabetic must maintain a hemoglobin A1c less than 7%, their blood pressure must remain below 130/80 and their good and bad cholesterol must be kept in range. The ABCs of Diabetes Care were established in order to reduces the chances of developing diabetic complications like neuropathy (nerve damage), nephropathy (kidney damage) and retinopathy (eye damage).

Here comes the perfect Insulin (code name Beta Juice) -a laboratory engineered balance of insulin, amylin, and C-peptide. Insulin to balance the blood sugar level, amylin to regulate fat and cholesterol levels and C-peptide to control the damage inflicted upon the micro vessels throughout the body. This is a GREAT IDEA!! Not just because it is MY idea, but because this is a huge opportunity to mitigate the complications that insulin by itself can impose, without the checks and balances of the other beta cell hormones. What do you say, Eli Lilly? You're halfway there!! You've already partnered with Amylin Pharmaceuticals. They have one third of this patent pie. Now hop on the horn and join forces with the C-peptide patent holder and ride your stock price to the moon. The diabetic girl has spoken. I know you care, Eli Lilly. Now put your money where your mouth is and make this new and improved insulin a light at the end of the diabetes tunnel.

A study suggests problems with cholesterol regulation in the insulin-producing cells of the pancreas may be responsible for the development of Type 2 diabetes.

A thesis paper written by a graduate student, Dr. Liam Brunham, addressed the fact that a dysfunction in cholesterol regulation is found in beta cells in the pancreas. A thought-provoking connection to this thesis was the fact that beta cells are the cells responsible for producing insulin. A beta cell expert decided to see what would happen if researchers genetically engineered mice without the ABCA1 gene. The ABCA1 gene is the gene responsible for cholesterol regulation in beta cells. Dr. Brunham appears to be the first to identify the role of cholesterol dysfunction resulting in the beta cells inability to properly secrete insulin.

This new research is promising and obviously raises questions in other researcher's minds. One is - what happens when amylin, a hormone produced by the beta cells, builds up to excess amounts? Does this, in fact, impair the beta cells' ability to function properly? Could this be another thesis that trumps Dr. Brunham's hunch for the cause of type 2 diabetes? Some researchers believe that the over-production of amylin and cholesterol may be due to a yet unidentified problem. Of course that is always an option. Science labs across the world could come to a screeching halt if doctor's stopped hypothesizing. As research continues, we will anxiously await the next best thesis paper, courtesy of our promising Graduate Students. Be cool - stay in school!

Neuropeptide regulating appetite may help in developing new diabetes treatments. The neuropeptide called melanin concentrating hormone (MCH) plays a role in the growth of insulin-producing beta cells and the secretion of insulin. MCH is found in the brain and regulates energy balance and appetite.

A previous study conducted at Joslin found an association between high levels of MCH and an increase in the number of beta cells in mice. When we eat food, our body needs more insulin. When MCH induces appetite, it simultaneously increased insulin secretion. This calls upon the beta cells and enhances their growth. If the proteins that mediate the growth mechanism can be identified, it could lead to the development of new drugs that would enhance beta cell growth to treat type 1 and type 2 diabetes.

Sounds great! However, this sounds similar to the function of SYMLIN, which is the synthetic form of amylin. Amylin is a hormone secreted by beta cells at the same time as insulin. If you've heard of Byetta - you've heard of Amylin Pharmaceuticals, the makers of SYMLIN. The researchers at Joslin and the guys at Amylin should get together and do lunch. They might have a lot to discuss between this research and the development of yet another biotechnological blockbuster drug.

The FDA has approved sitagliptin phosphate tablets to improve blood glucose levels in patients with type 2 diabetes. The drug, named Januvia, is proudly presented to the diabetic community by Merck and Co.

JANUVIA, a once-daily pill, enhances your body's natural ability to balance blood sugar levels. Your body sends important messages to your pancreas to try to balance high blood sugar. In response, your pancreas makes more insulin and signals the liver to make less sugar. But a substance in your body called DPP-4 blocks some of these important messages. JANUVIA works by blocking DPP-4, so more of the important messages get through. It also helps your pancreas make more insulin and signal your liver to make less sugar. Another feature of this new drug is the ability to prevent your sugar from going too low. JANUVIA works only when your blood sugar levels are high, or out of balance. When your blood sugar levels are at a healthy balance, JANUVIA doesn't have an effect. Because JANUVIA stops working before your blood sugar gets too low, it is not likely to lower your blood sugar to a potentially dangerous level (hypoglycemia). One more bonus to JANUVIA is the fact that this drug did not show weight gain in most patients during clinical trials.

Could this be the answer for your diabetes dilemma? Next time you swing by your doctor's office, mention that new drug Merck released. I'm sure your doctor will be as thrilled to see your numbers controlled as you'll be to see your natural ability to control them restored. Best of luck to those who find their diabetic solution in JANUVIA!

A Harvard Medical School scientist's experiments with fish discarded along the coast near Boston have led to a new class of diabetes drugs. The latest, from Novartis, may get U.S. approval this week.

In the late 1970s, Habener, a doctor specializing in diabetes care, began buying discarded fish to learn about the ways animals controlled blood sugar. By 1987 Habener discovered a protein in the pancreas of anglerfish that tells the pancreas to produce insulin. He called it glucagon-like peptide-1, or GLP-1. In 1995, researchers uncovered another use for Habener's discovery to treat diabetes. The scientists found an enzyme that digests GLP. By blocking the enzyme, they could increase the body's reserves of GLP, thereby raising insulin levels. Twenty years later, we will soon have the pleasure of meeting Novartis' concept for this chronology of discoveries in the form of liraglutide.

In clinical trials, patients taking liraglutide attained normal blood sugars without the common side effect of weight gain. In fact, liraglutide was more likely to make the patients slightly leaner. Depending on dosage and length of treatment, it may help patients to lose weight. The drug does not cause a change in appetite. Furthermore, none of the liraglutide patients experienced episodes of low blood sugar levels throughout the trials.

I'm no fisherman, but if all the seagulls of Big Pharma are swarming overhead - there's bound to be a school of fish below. However, this school is quite competitive. At last count, the five largest diabetic drug makers are using Habener's findings to create new medicines.

A brilliant doctor, a motivational mission, and the biggest names of the industry -- success is the only option. Taking Control Of Your Diabetes is a diabetic conference designed to educate and motivate people about diabetes.

Through informative expos, packed with field experts, enlightening workshops and crowds swarming with curiosity -- taking a more proactive role in your diabetes is as easy as showing up. A few hours at a TCOYD expo will cover a lot of territory. Whether you're interested in the latest developments in research, new medications, fresh ideas on diet and exercise, or legal and insurance guidance-- you're bound to find somebody who has an answer. TCOYD health fairs give you the chance to personally engage major manufacturers, doctors, entrepreneurs and innovators looking to help diabetics live a healthier life. Ask your questions. Try their products. They are there to help you. Tell them what you think. Tell them what you need.

Medical advances in diabetes care continue to out-pace improvements in patient care. Share something new with your doctor next visit. TCOYD delivers the information to the people who need it most. The mission of TCOYD is motivating, educating, and empowering diabetics and their loved ones. The success of this mission is defined by what you make of it.

The Food and Drug Administration recently approved Byetta as an add-on therapy to improve blood sugar control in people with type 2 diabetes who have not achieved adequate control on a thiazolidinedione, or TZD.

Byetta is already approved for treatment of patients with type 2 diabetes who are unsuccessful at controlling their blood sugar levels despite using the commonly prescribed oral medications or insulin. Byetta helps control blood glucose in four different ways. First, it signals your pancreas to make the right amount of insulin after you eat. It also stops your liver from making too much glucose when your body does not need it. It may reduce your appetite and the amount of food you eat. And it helps slow down how quickly food and glucose leave the stomach. It's no surprise that back in May, AMYLIN had to increase their production of Byetta, after realizing demand was outpacing the supply.

Byetta has given type 2 diabetics the reassurance they need to take their diabetes control to the next level. Taking your meds no longer has to come with the dubious consequence of a ravenous appetite. And with this new feather in the Byetta cap-the FDA says it does the trick to improve blood sugar control. The jury's out!

What is all the diabetic buzz about these days? Byetta and Exubera are certainly two biggies. My intention is to tantalize your interest in these juicy topics and leave a little to the imagination. Don't fret, I have a direct route to the quickest answers to any burning questions about these monster topics.

Byetta is getting a lot of attention nowadays. It comes from a poisonous lizard, the Gila monster. So quite literally, it really is monstrous. But don't let that discourage you from looking into it as a potential enhancement to your diabetes management. Many people have been pleased with its appetite suppressing, weight reducing attributes. Call it a shot of heroism -- since you must take it by injection. Traditional drugs to treat type 2 diabetes tend to cause a surge in appetite and weight gain. Could Byetta be the brute force to reckon with these dispiriting effects?

Exubera, what do you have to say for yourself? You can start by bragging that over 90% of the patients who tested you in clinical trials have chosen to continue using you. So the question is does this stuff work? It sounds like the answer is a resounding YES. Exubera is the newest form of insulin to hit the market since the debut of insulin, around 1890 (but please, don't quote me). You inhale it! The common concerns for this delivery of insulin include: how accurate is the dosing? What will be the long-term effects on your lungs? How long does the inhaled dose last? Will it need to accompany injections of longer-acting insulin? View the dLife TV interview with Dr. David Nathan, of Massachusetts General Hospital, and Ed a type 2 diabetic who has used Exubera for 9 years.

dLifeTV clears the air with answers to some of the common questions about Byetta and Exubera. Watch dLifeTV, airing every Sunday evening on CNBC, 7:00 PM on the East coast, 6:00 PM Central time and every Sunday morning on DIRECTV channel 251 at 7.30 AM Eastern time zone.

As a veteran type I diabetic, I often noticed the insatiable carb craving that insulin would cause. Until recently, I figured this was just another repercussion I dismissed as a hypochondriacal chemical imbalance. However, this past spring my doctor suggested that a new drug might help mitigate this side effect. Science has confirmed that when non-diabetics produce insulin, they simultaneously release a hormone called Amlyn. The synthetic form of this is SYMLIN. Well it's about time! I assure you, as certain as the sun rises in the East-it works!

SYMLIN slows down the movement of food through your stomach. This affects how fast sugar enters your blood after eating. SYMLIN also helps you to feel full more quickly during meals, causing you to eat less than you normally would. SYMLIN is always used with insulin to help lower blood sugar during the 3 hours after meals. You may have already heard of its sibling: BYETTA. Amylin manufactures both, SYMLIN and BYETTA. There's a chemical juxtaposition, but I'm no rocket scientist. Anybody want to take a stab at it?

SYMLIN is not an ideal drug for every diabetic. It does have its side effects, the most pronounced being nausea. However, if you've been searching for an agent to quell the search and destroy mission insulin conveys to your appetite - SYMLIN might be your new friend on the battlefield.

No one said managing diabetes is cheap, and here's more proof. On Friday, San Diego-based Amylin Pharmaceuticals announced it is raising the prices of its diabetes drugs, Byetta and Symlin injections. Byetta has been in the new lately because of its weight loss effects. Symlin is a non-insulin mealtime treatment. The drugmaker says the wholesale cost for a 5-microgram-per-dose pen of Byetta increased from $147 to $156 and a vial of Symlin jumped to $86 from $80. Price hikes were effective Thursday.